Press Releases - 2022-12-13

Date	Title	Company
13-Dec-2022	Technology training lacking for over half of manufacturers	Visual Components
13-Dec-2022	Bovine Lactoferrin Market to expand at a 15.8% value CAGR by 2033 \| Says FMI Analyst	MARKITWIRED
13-Dec-2022	Blood clotting research holds hope for sepsis	University of Birmingham
13-Dec-2022	PLANNING APPLICATION SUBMITTED AT CANARY WHARF FOR EUROPE’S LARGEST AND MOST TECHNOLOGICALLY ADVANCED LIFE SCIENCES BUILDING	Canary Wharf Group
13-Dec-2022	MedTech Flanders becomes part of MEDVIA, Flanders’ healthtech spearhead cluster	MEDVIA
13-Dec-2022	Green Bioactives completes £2.6m seed financing to advance its sustainable plant products biomanufacturing platform	Green Bioactives
13-Dec-2022	Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases	Sosei Heptares
13-Dec-2022	Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO	Kindeva
13-Dec-2022	First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)	Businesswire
13-Dec-2022	Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma	Janssen
13-Dec-2022	PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting	PureTech
13-Dec-2022	Genomic Biopharma and patient advocacy organization POIC e dintorni APS partner to offer whole genome sequencing to bring better treatments and cures to those living with gastrointestinal diseases	Genomic Biopharma
13-Dec-2022	Diabetes self-management app intellin® is a cost-effective solution for preventing diabetic foot ulcer recurrence	Gendius
13-Dec-2022	1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors	1ST Biotherapeutics, Inc.
13-Dec-2022	Advicenne Obtains Orphan Drug Designation for ADV7103 in the United States for the Treatment of Distal Renal Tubular Acidosis (dRTA)	Businesswire
13-Dec-2022	Retinal Disorder Treatment Market is projected to accelerate at a CAGR of 7.7% from 2023 to 2032 \| insightSLICE	insightSLICE
13-Dec-2022	Diagnostic Electrocardiograph (ECG) Market is geared to grow at a CAGR of 6.3% from 2023 to 2032 \| insightSLICE	insightSLICE
13-Dec-2022	Electrosurgery Market is anticipated to expand at a CAGR of 5.2% from 2023 to 2032 \| insightSLICE	insightSLICE
13-Dec-2022	Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas	Spexis AG
13-Dec-2022	Relief Therapeutics Announces Issuance of Shares from Authorized Capital	Relief Therapeutics Holding SA